Gene therapy, chemo, and immunotherapy before bladder cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new treatment combination before bladder removal surgery for muscle-invasive bladder cancer. It uses a special virus-delivered gene therapy (nadofaragene firadenovec) plus two chemotherapy drugs (cisplatin and gemcitabine) and an immunotherapy drug (durvalumab) to try to shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have muscle-invasive bladder cancer (cancer that has grown into the muscle layer of the bladder), and be planning to have your bladder removed.
- You must be healthy enough to receive a combination of chemotherapy (cisplatin and gemcitabine) and an immunotherapy drug (durvalumab) before surgery.
- Your blood counts and kidney and liver function must be within certain limits.
- You cannot have already had chemotherapy for this bladder cancer or have other active cancers, and you cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs (futibatinib and durvalumab) given before bladder removal surgery for people with muscle-invasive bladder cancer who cannot take standard cisplatin chemotherapy. The goal is to see if the combination shrinks the tumor and improves outcomes.
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
This trial checks if a DNA blood test can help decide who needs extra chemo after bladder or upper urinary tract cancer surgery. It tests whether watching for cancer DNA in the blood can match patients to the right treatment.
This trial tests a tiny device placed into bladder tumors before surgery to see which drugs might work best for each patient, helping guide future treatment choices.
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial tests a new antibody-drug (RC48-ADC) together with an immunotherapy medicine (triplizumab) given before bladder surgery. It’s for people with HER2-positive muscle-invasive bladder cancer who may benefit from shrinking the tumor before radical cystectomy.
Hear when a new Muscle Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.